Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$11.26 -0.67 (-5.62%)
At close: Oct 1, 2026 · 4:00 PM EDT

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026)

Updated

Monte Rosa Therapeutics' Cash from Financing Activities was $3.21 million in Q2 2026, up 779.7% from $365,000 a year earlier but down 99.0% from the prior quarter.

Analysis

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, Monte Rosa Therapeutics' Cash from Financing Activities was $361.52 million through Jun 30, 2026; for FY2025, it was $30.35 million, down 69.3% from FY2024.

  • Cash from Financing Activities shows a five-year compound annual growth rate of -12.8% (FY2020 to FY2025).
  • In earlier years, Cash from Financing Activities was $98.89 million in FY2024 (+259.7%), $27.49 million in FY2023 (+34.3%), $20.47 million in FY2022 (-94.6%) and $377.56 million in FY2021 (+528.6%).
  • Quarterly Cash from Financing Activities has moved between -$217,000 (Q3 2022) and $328.34 million (Q1 2026) over five years.
  • Compared with a year earlier, Cash from Financing Activities was higher in 1 of the last five quarters, with growth averaging 77.9%.
  • The best year-over-year quarter for Cash from Financing Activities over five years was Q2 2026 (growth of 779.7%); the worst was Q2 2022 (a decline of 100.0%).
  • Per Business Quant data, GLUE's Cash from Financing Activities in the three quarters before Q2 2026 was $328.34 million (Q1 2026), $29.62 million (Q4 2025) and $348,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Monte Rosa Therapeutics 1.02 Bn 428.56 Mn - 3.21 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.21 Mn
Mar 31, 2026 328.34 Mn
Dec 31, 2025 29.62 Mn
Sep 30, 2025 348,000.00
Jun 30, 2025 365,000.00
Mar 31, 2025 14,000.00
Dec 31, 2024 608,000.00
Sep 30, 2024 15,000.00
Jun 30, 2024 98.02 Mn
Mar 31, 2024 246,000.00
Dec 31, 2023 25.17 Mn
Sep 30, 2023 1.10 Mn
Jun 30, 2023 1.20 Mn
Mar 31, 2023 18,000.00
Dec 31, 2022 20.43 Mn
Sep 30, 2022 -217,000.00
Jun 30, 2022 96,000.00
Mar 31, 2022 153,000.00
Dec 31, 2021 -135,000.00
Sep 30, 2021 29.46 Mn
API Access

Monte Rosa Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=GLUE&period=max&api_key=YOUR_API_KEY